Galecto, Inc.

Galecto, Inc. develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto a unique platform.

Contact name:

Hans Schambye


Ole Maaløes Vej 3, 2200 Copenhagen, Denmark

Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 7172 1114

Copyright 2012 DANISH BIO – DANSK BIOTEK. All rights reserved.